Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EBT (2017 - 2025)

Historic EBT for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$78.6 million.

  • Autolus Therapeutics' EBT rose 424.75% to -$78.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$220.2 million, marking a year-over-year increase of 1850.58%. This contributed to the annual value of -$219.1 million for FY2024, which is 514.97% down from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' EBT is -$78.6 million, which was up 424.75% from -$47.5 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' EBT registered a high of -$7.4 million during Q4 2022, and its lowest value of -$39.4 billion during Q3 2021.
  • Moreover, its 5-year median value for EBT was -$45.5 million (2023), whereas its average is -$2.1 billion.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 8705360.78% in 2021, then soared by 9989.14% in 2022.
  • Quarter analysis of 5 years shows Autolus Therapeutics' EBT stood at -$24.1 million in 2021, then surged by 69.23% to -$7.4 million in 2022, then crashed by 939.1% to -$77.2 million in 2023, then surged by 66.13% to -$26.1 million in 2024, then tumbled by 200.59% to -$78.6 million in 2025.
  • Its last three reported values are -$78.6 million in Q3 2025, -$47.5 million for Q2 2025, and -$67.9 million during Q1 2025.